The choice of the diagnostic biomarkers of acute coronary syndromes;Izbor biohemijskih pokazatelja za dijagnostikovanje akutnog koronarnog sindroma

Jugoslovenska Medicinska Biohemija

Volumn 24, Issue 1, 2005, Pages 1-13

  Majkić Singh, Nada ^a,b  

^a Institut za Medicinsku Biohemiju   (Yugoslavia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Acute coronary syndromes; B type natriuretic peptide; Cardiac troponins; CONSORT; Diagnostic markers; STARDT

Indexed keywords

ALBUMIN; AMINO ACID; ASPARTATE AMINOTRANSFERASE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE; CREATINE KINASE BB; CREATINE KINASE MB; CREATINE KINASE MM; CYTOKINE; FATTY ACID; GLYCOGEN PHOSPHORYLASE; LACTATE DEHYDROGENASE; MYOGLOBIN; NATRIURETIC FACTOR; PADGEM PROTEIN; PHOSPHOLIPASE D; STEROID; TROPONIN C; TROPONIN I; TROPONIN T;

COLORIMETRY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PREDICTION; REVIEW; STANDARD;

EID: 13244252421     PISSN: 03543447     EISSN: None     Source Type: Journal    
DOI: 10.2298/JMH0501001M     Document Type: Review

References (85)

1. Aroney CN, de Lemos JA. Management of Acute Coronary Syndromes. In. Cardiac Markers. Edited by Alan H.B. Wu. Second Edition, Humana Press, 2003, 15-36.
2. Joint ESC/ACC Committee. Myocardial infarction redefined- a consensus document of the Joint European Society of Cardiology/Americal College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-69.
3. Yamagishi M, Terashima M, Awano K, et. al. Morphology of vulnerable coronary plaque: uinsights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol 2000; 35: 106-11.
4. Gerhard W, Katus H, Ravkilde J, et al. S-troponin T in suspected ischemic myocardial injury compared with mass and catalytic concentrations of S-cretinine kinase isoenzyme MB. Clin Chem 1991; 37: 1405-11.
5. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146-50.
6. Tucker JF, Collins RA, Anderson AJ, Hauser J, Kalas J, Aplle FS. Early diagnostic efficiency of cardiac troponin I and troponin T for acute myocarial infarction. Acad Emerg Med 1997; 4: 13-21.
7. O'Neil BJ, Ross MA. Cardiac markers protocols in a chest pain observation unit. Emerg Med Clin North Am 2001; 19: 67-86.
8. Blomkalns AL, Gibler WB. Early Detection of Myocardial Necrosis in the Emergency Setting and utility of Serum Biomarkers in Chest Pain unit Protocols. In Cardiac Markers, Second Edition, Ed by Alan H.B Wu, Humana Press, 2003; 3-13.
9. Begg C, Cho M, Eastwaood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomnized controlled trals: the CONSORT statement. JAMA 1996; 276: 637-9.
10. Bossuyt PM, Reitdma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, et al. The STARD Statement for Reporting Studied of Diagnostic Accuracy: Explanation and Elaboration. Clin Chem 2003; 49: 7-18.
11. McQueen M. Evidence-based laboratory medicine: addressing bias, generalisability and applicability in studies on diagnostic accuracy: The STARD initiative. Clin Biochem (Editorial) 2003; 36: 1-7.
12. Majkić-Singh N. Uloga laboratorijske medicine zasnovane na dokazima u zdravstvenoj službi. Jugoslov Med Biochem 2002; 21: 99-104.
13. Majkić-Singh N. Novi biohemijski markeri oštećenja miokarda. Jugoslov Med Biochem 1999; 18: 61-132.
14. Slate EH, Turnbull BW. Statistical models for longitudinal biomarkers of disease. Stat Med 2000; 19: 617-37.
15. Azzazy HME, Christenson RH. Cardiac markers of acute coronary syndromes: is there a case for point-of care testing? Clin Biochem 2002; 35: 13-27.
16. Balk EM, Ioannidis JP, Salem D, Chew PW, Lau J. Accuracy of biomarkers to diagnose acute cardiac ischemia in the emergency department: a meta-analysis. Ann Emerg Med 2001; 37: 478-94.
17. Ioannidis JP, Salem D, Chew PW, Lau J. Accuracy of imaging technologies in the diagnosis of acute cardiac ischemia in the emergency department: a meta analysis. Ann Emerg Med 2001; 37: 471-7.
18. Chan B, Dodsworth N, Woodrow J, Tucker A, Harris R. Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem 1995; 227: 524-8.
19. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism off a new assay for myocardial ischemia. Eur J Biochem 2001; 268: 42-7.
20. Christenson RH, Duh SH, Sanhai WR, et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicentre study. Clin Chem 2001; 47: 467-70.
21. Bar-Or D, Winkler JV, Vanbenthuysen K, Karris L, Lau E, Hetzel FW. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine cinase-MB, myoglobin, and troponin I. Am Heart J 2001; 141: 985-91.
22. Morrow DA, de Lemos JA, Sabatine MS, Antman EM. The Search for a Biomarker of Cardiac Ischemia. Clin Chem 2003; 49: 537-9.
23. Wardman P, Candeias LP. Fenton Centennial Symposium. Fenton chemistry: an introduction. Radiat Res 1996; 145: 523-31.
24. Samuni A, Aronovitch J, Godinger D, Chevion M, Czapski G. On the cytotoxicity of vitamin C and metal ions. A site-specific Fenton mechanism. Eur J Biochem 1983; 137: 119-24.
25. Marx G, Chevion M. Site-specific modification of albumin ny free radicals. Biochem J 1985; 236: 397-400.
26. McCord JM. Oxygen-derived free radicals in past-ischemic tissue injury. N Engl J Med 1985; 312: 159-63.
27. Laussac JP, Sarkar B. Characterization of the copper (II)- and nickel (II)-transport site of human serum albumin. Studies of cooper (II) and nickel (II) binding to peptide 1-24 of human serum albumin ny 13C and 1H NMR spectroscopy. Biochemistry 1984; 23: 2832-8.
28. Bal W, Christodoulou J, Sadler P, Tucker A. Multi-metal binding site of serum albumin. J Inorgan Biochem 1998; 70: 33-9.
29. Glennon JD, Sarkar B. Nickel (II) transport in human bood serum, Studies of nickel (II) binding to human albumin and to native-sequence peptide, and ternary-complex formation with L-histidine. Biochem J 1998; 203: 15-23.
30. Bar-Or D, Lau E, Winkler J. A novel assay for the cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. J Emerg Med 2000; 19: 311-5.
31. Painter PC, Branham E, Morris D, et al. Analytical studies of an assay to detect myocardial ischemia. Clin Chem 2000; 47: A75.
32. Apple FS, Quist HE, Otto AP, Mathews WE, Marakama MM. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem 2002; 48: 1097-100.
33. Christenson RL, Duh SH, Sanhai WR, et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001; 47: 464-70.
34. Wu AHB, Morris DL, Fletcher DR, Apple FS, Christenson RH, Painter PC. Analysis of the Albumin Cobalt Binding (ACBTM) test as an adjunct troponin I for the early detection of acute myocardial infarction. Cardiovasc Toxicol 2001; 1: 147-52.
35. Morris DL, Fletcher DR, Apple FS, et al. The Albumin Cobalt Binding test (ACB Test) as an adjunct to troponin for early diagnosis of acute myocardial infarction. Eur Heart J 2001; 22 (Suppl); P608.
36. Heller GV, Cyr G, Storrow AB, et al. The Albumin Cobalt Binding test (ACBTM Test) to diagnose ischemia in patients with symptoms of coronary artery disease. Clin Chem 2001; 47(S6): A205.
37. Bhagavan NV, Lai EM, Rios PA, Yang J, et al. Evaluation of Human Serum Albumin Cobalt Binding Assay for the assessment of Myocardial Ischemia and Myocardial Infarction. Clin Chem 2003; 49: 581-5.
38. Kurien VA, Oliver MF. A metabolic cause of arrhythmias. Lancet 1970; 1: 813-5.
39. Jouven X, Charles MA, Desnos M, Ducimetiere P. Circulating nonesterified fatty acid concentration as a positive risk factor for sudden death in the population. Circulation 2001; 104: 756-61.
40. Kleindeld AM, Prothro D, Brown DL, Dais RC, Richieri GV, DeMaria A. Increases in serum unbound free fatty acis concentrations following coronary angioplasty. Am J Cardiol 1996; 78: 1350-4.
41. Morris AJ, Frohman MA, Engebrecht J. Measurement of phospholipase D activity. Analyt Biochem 1997; 252: 1-9.
42. Garcia JG, Fenton JW, Natarajan V. Thrombin stimulation of human endothelial cell phospholipase D activity. Regulation ny phospholipase C, protein kinase C, and cyclic adenosine 3′5′-monophosphate. Blood 1992; 79: 2056-67.
43. O'Brien KD, Pineda C, Chiu WS, Bowen R, Deeg MA. Glycosylphosphatidylinositol-specific phospholipase D is expressed by macrophaged in human atherosclerosis and colocalizes with oxidation epitopes. Circulatrion 1999; 79: 2056-67.
44. Houle MG, Bourgoin S. Regulation of phospholipase D by phosphorylation-dependent mechanisms. Biochim Biophys Acta 1999; 1439: 135-49.
45. Deves R, Krupka RM. The comparative specificity of the inner and outher substrate transfer sites in the choline carrier of human ertythrocytes. J Membr Biol 1984; 80: 71-80.
46. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: Is their assay merely a marker of cardiac disease? (opinion article). Clin Chem Lab Med 2002; 40: 752-60.
47. Clerico A, Iervasi G, Pilo A. Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. Curr Drug Metab 2000; 1: 85-105.
48. Collinson PO, John C, Cramp DRG, Canepa-Anson R. Prospective randomised controlled trial of point of care testing with central laboratory testing for cardiac enzyme measurement. (Abstract.) Clin Chem 1998; 44: A69.
49. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular diseases. Clin SCi 1998; 95: 519-29.
50. Suzuki T, Yamazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc res 2001; 51: 489: 94.
51. Mair J, Hammerar-Lercher A, Puchandorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of hearth failure. Clin Chem Lab Med 2001; 39: 571-88.
52. Chen HH, Burnette JC Jr. Natriuretic peptides in the pathophysiology of congestive hearth failure. Cur Cardiol Rep 2000; 2: 198-205.
53. Struthers AD. Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart 2002; 87: 97-8.
54. Katus HG, Remppis A, Scheffold T. Intracellular compartementation of cardiac troponin T and its relase kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 1991; 676: 1360-67.
55. Mair J. Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage. Clin Chim Acta 1998; 272: 79-86.
56. Panthegini M. Biochemical Markers of Cardiac Diseases. Jugoslov Med Biochem 2004; 23: 201-11.
57. Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L. The prognostic value of serum troponin in unstable angina. N Engl J Med 1992; 327: 146-50.
58. Report of the Joint International Society, and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 1979; 59: 607-9.
59. Savonitto S, Fusco R, Granger CB, Cohen MG, Thompson TD, Ardissino D, Califf RM. Clinical, electrocardiograph, and biochemical data for immediate risk stratification in acute coronary syndromes. Ann Noninvasive Electrocardial 2001; 6: 64-77.
60. Christensonm RH, Azzaty HME. Biochemical markers of the acute coronary syndromes. Clin Chem 1998; 44: 1855-64.
61. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/Am College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2002; 36: 959-69.
62. Plebani M, Zaninotto M. Diagnostic strategies using myoglobin measurement in myocardial infarction. Clin Chim Acta 1998; 272: 69-77.
63. Lott JA, Stang JM. Differential diagnosis of patients with abnormal serum creatine kinase isoenzymes. Clin Lab Med 1989; 9: 627-642.
64. Horder M, Elser RC, Gerhardt W, Mathieu M, Sampson EJ. International Federation of Clinical Chemistry, Scientific Division Committee on Enzymes: approved recommendation on IFCC methods for the measurement of catalytic concentration of enzymes. Part 7. IFCC method for creatine kinase (ATP: creatine: N-phoshotransferase, EC 2.7.3.2). Eur J Xlin Chem Clin Biochem 1991; 29: 431-56.
65. Henderson AR, McQueen MJ, Patten RL, et al. Testing for creatine kinase and creatine kinase-2 in Ontario: reference ranges and assay types. Clin Chem 1992; 38: 1365-70.
66. Smith AF. Separation of tissue and serum creatine kinase isoenzymes on polyacrylamide gel slabs. Clin Chim Acta 1972; 39: 351-9.
67. Wevers RA, Delsing M, Gebbink JAG, Soons JBJ. Post-synthetic changes in creatine kinase isozyme. Clin Chem Acta 1978; 86: 323-7.
68. Secchiero S, Altinier S, Zaninotto M, Lachin M, Plebani M. Evaluation of a new automated system for the determination of CK-MB isoforms. J Clin Lab Anal 1995; 9: 359-65.
69. Suzuki T, Shiraishi T, Tomita K, Totani M, Murachi T. Monoclonal antibody inhibiting creatine kinase MM3 but not isoform MM1. Clin Chem 1990; 36: 153-6.
70. Wu AHB. Creatine kinase isoforms in ischemic hearth disease Review. Clin Chem 1989; 35: 7-13.
71. Mair J, Puschendorf B, Michel G. Clinical significance of cardiac contractile proteins for the diagnosis of myocardial injury. Adv Clin Chem 1994; 31: 63-98.
72. Apple FS, Sharkey SW, Falafati A, et al. Assessment of left ventricular function using serum cardiac troponin I measurements following myocardial infarction. Clin Chim Acta 1998; 272: 59-67.
73. Aranega AE, Reina A, Velez C, Alvarez L, Melguizo C, Arange A. Circulating alpha-actin in angina pectoris. J Mol Cell Cardiol 1993; 25: 15-22.
74. Majkić-Singh, N. Enzimi kod srčanih oboljenja. Klinička enzimologija, AID Praktikum, Beograd, 1993; 228-254.
75. Majkić-Singh, N. Biohemijski parametri za dijagnostikovanje infarkta miokarda. Infarm 1998; 4: 18-19.
76. Majkić-Singh, N. Novi biohemijski marked oštećenja miokarda. Arhiv za farmaciju 1998; 5: 577.
77. Bareford D, Hayling A. Inappropriate use of laboratory services: long term combined approach to modify request patterns. BNJ 1990; 301: 1305-7.
78. Perraro F, Rossi P, Liva C, Bulfoni A, Ganzani G, Tonutti E, et al. Inappropriate emergency test ordering in a genarl hospital: preliminary reports. Qual Assur Health Care 1992; 4: 77-81.
79. Van Walraven C, Naylor D. Do we know what inappropriate laboratory utilization is? A systematic review of laboratory audits. JAMA 1998; 280: 550-8.
80. Price CP. Improving the quality of peer reviewed literature on diagnostic tests: the STARD initiative. (Guest Editorial). Clin Chim Acta 2003; 334: 1-3.
81. Evidence-Based Medicine Working Group. Evidence-based medicine: a new approach to the teaching of medicine. JAMA 1992; 268: 2420-5.
82. Wolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J, et al. Clinical guidelines: potential benefits, limittations, and harms of clinical guidelines. BMJ 1999; 318: 527-30.
83. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Chem 2003; 49: 1-6.
84. http://www.consort-statement.org/stardstatement.htm.
85. Balk E. Heart Disease. In Evidence-based medicine. Optimizing Decision-Making to Improve Patient Care. Proceeding from the Evidence-Based Medicine Conference. May 19-20, 2000 Washington, DC, 20-23.